Phase II Evaluation of Safety, Tolerability, and Efficacy of BI 730357 in Patients With Moderate-to-severe Plaque Psoriasis
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2019
At a glance
- Drugs BI 730357 (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 24 Sep 2018 Status changed from not yet recruiting to recruiting.
- 24 Aug 2018 New trial record
- 20 Aug 2018 Planned initiation date changed from 24 Aug 2018 to 17 Sep 2018.